Related Experiment Video

Updated: Jun 10, 2026

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease
06:25

Ex Vivo Culture of Circulating Tumor Cells in the Cerebral Spinal Fluid from Melanoma Patients to Study Melanoma-Associated Leptomeningeal Disease

Published on: March 29, 2024

Insulin-like growth factor receptor type I as a target for cancer therapy

Liliane Goetsch1, Nathalie Corvaïa

  • 1Centre d'Immunologie Pierre Fabre, 5 avenue Napoléon III, F-74164 Saint Julien-en-Genevois, France. liliane.goetsch@pierre-fabre.com

Immunotherapy
|July 20, 2010
PubMed

Insights

Insulin-like growth factor receptor I (IGF-IR) is a promising target for cancer therapy. Research focuses on developing IGF-IR inhibitors and biomarkers for effective patient selection in clinical trials.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer therapy is advancing with new molecular targets identified through improved oncogenesis understanding.
  • Inhibition of tyrosine kinase receptor activity offers new therapeutic opportunities for cancer growth control.
  • Insulin-like growth factor receptor I (IGF-IR) has emerged as an attractive target for drug development after extensive research.

Purpose of the Study:

  • To review current knowledge on IGF-IR as a therapeutic target.
  • To provide an overview of ongoing clinical trials involving IGF-IR.
  • To highlight challenges and opportunities in developing IGF-IR targeted therapies.

Main Methods:

  • Review of scientific literature on IGF-IR.
  • Analysis of ongoing clinical trials for anti-IGF-IR therapies.
  • Discussion of drug development strategies and biomarker discovery.

Main Results:

  • IGF-IR shows promise as a target due to its role in oncogenesis.
  • Antibody design leveraging IGF-IR's homology to insulin receptor is feasible.
  • Significant investment is being made in evaluating IGF-IR inhibitors in human trials.

Conclusions:

  • IGF-IR targeted therapies, including monoclonal antibodies, represent a significant area of development in oncology.
  • Biomarker discovery for efficacy and patient selection is crucial for successful clinical application of anti-IGF-IR treatments.
  • Further research and clinical trials are needed to optimize the use of IGF-IR inhibitors in combination therapies.

More Related Videos

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles08:35

Therapeutic Gene Delivery and Transfection in Human Pancreatic Cancer Cells using Epidermal Growth Factor Receptor-targeted Gelatin Nanoparticles

Published on: January 4, 2012

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Insulin: The Receptor and Signaling Pathways01:28

Insulin: The Receptor and Signaling Pathways

Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include: